Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 191.24
ARDM's Cash to Debt is ranked higher than
67% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ARDM: 191.24 )
Ranked among companies with meaningful Cash to Debt only.
ARDM' s 10-Year Cash to Debt Range
Min: 0.29  Med: 5.25 Max: No Debt
Current: 191.24
Equity to Asset 0.70
ARDM's Equity to Asset is ranked higher than
62% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ARDM: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
ARDM' s 10-Year Equity to Asset Range
Min: -1.83  Med: 0.53 Max: 0.93
Current: 0.7
-1.83
0.93
F-Score: 4
Z-Score: -4.64
M-Score: 7.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -11.69
ARDM's Operating margin (%) is ranked lower than
81% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. ARDM: -11.69 )
Ranked among companies with meaningful Operating margin (%) only.
ARDM' s 10-Year Operating margin (%) Range
Min: -9165.74  Med: -236.37 Max: -11.49
Current: -11.69
-9165.74
-11.49
Net-margin (%) -11.95
ARDM's Net-margin (%) is ranked lower than
81% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. ARDM: -11.95 )
Ranked among companies with meaningful Net-margin (%) only.
ARDM' s 10-Year Net-margin (%) Range
Min: -9007.17  Med: -221.92 Max: 13.86
Current: -11.95
-9007.17
13.86
ROE (%) -10.71
ARDM's ROE (%) is ranked lower than
78% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. ARDM: -10.71 )
Ranked among companies with meaningful ROE (%) only.
ARDM' s 10-Year ROE (%) Range
Min: -808.13  Med: -114.93 Max: 12.78
Current: -10.71
-808.13
12.78
ROA (%) -8.08
ARDM's ROA (%) is ranked lower than
77% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ARDM: -8.08 )
Ranked among companies with meaningful ROA (%) only.
ARDM' s 10-Year ROA (%) Range
Min: -102.39  Med: -49.16 Max: 8.91
Current: -8.08
-102.39
8.91
ROC (Joel Greenblatt) (%) -842.42
ARDM's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. ARDM: -842.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3534.16  Med: -278.02 Max: 1095.34
Current: -842.42
-3534.16
1095.34
Revenue Growth (3Y)(%) 137.60
ARDM's Revenue Growth (3Y)(%) is ranked higher than
99% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. ARDM: 137.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARDM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -81.3  Med: -12.50 Max: 137.6
Current: 137.6
-81.3
137.6
» ARDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ARDM Guru Trades in Q2 2014

First Eagle Investment 3,854,730 sh (New)
» More
Q3 2014

ARDM Guru Trades in Q3 2014

First Eagle Investment 3,854,730 sh (unchged)
» More
Q4 2014

ARDM Guru Trades in Q4 2014

First Eagle Investment 3,854,730 sh (unchged)
» More
Q1 2015

ARDM Guru Trades in Q1 2015

Steven Cohen 321,485 sh (New)
First Eagle Investment 3,854,730 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.89
ARDM's P/B is ranked higher than
59% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. ARDM: 2.89 )
Ranked among companies with meaningful P/B only.
ARDM' s 10-Year P/B Range
Min: 0.76  Med: 3.03 Max: 215
Current: 2.89
0.76
215
P/S 3.09
ARDM's P/S is ranked higher than
54% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. ARDM: 3.09 )
Ranked among companies with meaningful P/S only.
ARDM' s 10-Year P/S Range
Min: 1.21  Med: 8.09 Max: 145.45
Current: 3.09
1.21
145.45
PFCF 15.00
ARDM's PFCF is ranked higher than
89% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. ARDM: 15.00 )
Ranked among companies with meaningful PFCF only.
ARDM' s 10-Year PFCF Range
Min: 11.31  Med: 14.93 Max: 397.35
Current: 15
11.31
397.35
POCF 15.64
ARDM's POCF is ranked higher than
77% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. ARDM: 15.64 )
Ranked among companies with meaningful POCF only.
ARDM' s 10-Year POCF Range
Min: 10.81  Med: 15.42 Max: 794.7
Current: 15.64
10.81
794.7
Current Ratio 6.33
ARDM's Current Ratio is ranked higher than
84% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. ARDM: 6.33 )
Ranked among companies with meaningful Current Ratio only.
ARDM' s 10-Year Current Ratio Range
Min: 0.94  Med: 3.98 Max: 21.99
Current: 6.33
0.94
21.99
Quick Ratio 6.33
ARDM's Quick Ratio is ranked higher than
85% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. ARDM: 6.33 )
Ranked among companies with meaningful Quick Ratio only.
ARDM' s 10-Year Quick Ratio Range
Min: 0.94  Med: 3.98 Max: 21.99
Current: 6.33
0.94
21.99
Days Sales Outstanding 5.22
ARDM's Days Sales Outstanding is ranked higher than
96% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. ARDM: 5.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARDM' s 10-Year Days Sales Outstanding Range
Min: 1.26  Med: 14.93 Max: 571.49
Current: 5.22
1.26
571.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.25
ARDM's Price/Net Cash is ranked higher than
85% of the 181 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.71 vs. ARDM: 3.25 )
Ranked among companies with meaningful Price/Net Cash only.
ARDM' s 10-Year Price/Net Cash Range
Min: 1.47  Med: 6.02 Max: 362.93
Current: 3.25
1.47
362.93
Price/Net Current Asset Value 3.05
ARDM's Price/Net Current Asset Value is ranked higher than
82% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.66 vs. ARDM: 3.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARDM' s 10-Year Price/Net Current Asset Value Range
Min: 1.44  Med: 4.58 Max: 88.72
Current: 3.05
1.44
88.72
Price/Tangible Book 2.78
ARDM's Price/Tangible Book is ranked higher than
62% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. ARDM: 2.78 )
Ranked among companies with meaningful Price/Tangible Book only.
ARDM' s 10-Year Price/Tangible Book Range
Min: 1.25  Med: 3.14 Max: 190
Current: 2.78
1.25
190
Price/Projected FCF 10.27
ARDM's Price/Projected FCF is ranked lower than
83% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. ARDM: 10.27 )
Ranked among companies with meaningful Price/Projected FCF only.
ARDM' s 10-Year Price/Projected FCF Range
Min: 9.03  Med: 23.03 Max: 73.77
Current: 10.27
9.03
73.77
Price/Median PS Value 0.37
ARDM's Price/Median PS Value is ranked higher than
96% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. ARDM: 0.37 )
Ranked among companies with meaningful Price/Median PS Value only.
ARDM' s 10-Year Price/Median PS Value Range
Min: 0.15  Med: 0.89 Max: 16.85
Current: 0.37
0.15
16.85
Earnings Yield (Greenblatt) (%) -6.92
ARDM's Earnings Yield (Greenblatt) (%) is ranked lower than
85% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. ARDM: -6.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARDM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -7.47  Med: 743.70 Max: 7148.8
Current: -6.92
-7.47
7148.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Aradigm Corp, a California corporation was incorporated on January 30, 1991 . It is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. The Company's development candidates include proprietary formulations of the potent antibiotic ciprofloxacin or Pulmaquin ARD-3150 and Lipoquin ARD-3100 that are delivered by inhalation for the management of infections associated with the severe respiratory diseases such as non-cystic fibrosis bronchiectasis and cystic fibrosis. Its proprietary programs under development include, Inhaled Ciprofloxacin and Smoking Cessation Therapy. Ciprofloxacin has been approved by the FDA as an anti-infective agent and is widely used for the acute treatment of a variety of bacterial infections, including exacerbations associated with pulmonary infections. ARD-1600 Inhaled Nicotine is used for Smoking Cessation Therapy. It competes with pharmaceutical and biotechnology companies, hospitals, research organizations, individual scientists and nonprofit organizations engaged in the development of drugs and other therapies for the respiratory disease indications. It had 74 issued United States patents, with 14 additional United States patent applications pending. The research, development, testing, manufacturing, labeling, advertising, promotion, distribution, marketing and export, among other things, of any products it develops are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for ARDM

Headlines

Articles On GuruFocus.com
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 
Eveillard’s First Eagle Seizes 45% of Pharamaceutical Company, Aradigm Dec 19 2012 

More From Other Websites
Aradigm (ARDM) is Overbought: Is A Drop Coming? - Tale of the Tape Jun 10 2015
Aradigm Corporation (ARDM) in Focus: Stock Jumps 5.5% - Tale of the Tape Jun 10 2015
ARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 18 2015
ARADIGM CORP Financials May 16 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... May 14 2015
10-Q for Aradigm Corp. May 13 2015
Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm's Liposomal... May 12 2015
Results from Pulmonary Non-Tuberculous Mycobacteria (PNTM) Study Using Aradigm’s Liposomal... May 12 2015
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 11 2015
Aradigm Announces First Quarter 2015 Financial Results May 11 2015
Aradigm reports 1Q loss May 11 2015
Aradigm Announces First Quarter 2015 Financial Results May 11 2015
10-K for Aradigm Corp. May 03 2015
Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry,... Apr 21 2015
Aradigm Announces Appointment of Dr. Robert A. Reed as Vice President, Regulatory (Chemistry,... Apr 21 2015
Aradigm to Host Key Opinion Leader Breakfast and Webcast on April 23 in New York City Apr 16 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of... Mar 20 2015
ARADIGM CORP Files SEC form 10-K, Annual Report Mar 18 2015
ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 17 2015
Aradigm Announces Fourth Quarter 2014 and Full Year Financial Results Mar 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK